Author

N. Ohmagari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:database / resource· 1 Assay:proteomics· 1

Frequent Co-Authors

K. Iwatsuki-Horimoto· 3 shared M. Imai· 3 shared M. Kiso· 3 shared Y. Kawaoka· 3 shared Y. Sakai-Tagawa· 3 shared K. Maeda· 2 shared M. Ito· 2 shared N. Kinoshita-Iwamoto· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. Iwatsuki-Horimoto

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Characterization of an EG.5.1 clinical isolate in vitro and in vivo

R. Uraki, M. Kiso, K. Iwatsuki-Horimoto, S. Yamayoshi, M. Ito, S. Chiba, Y. Sakai-Tagawa, M. Imai, Y. Kashima, M. Koga, N. Fuwa, N. Okumura, M. Hojo, N. Iwamoto, H. Kato, , Y. Kawaoka

This study characterizes the in vitro and in vivo properties of the EG.5.1 SARS-CoV-2 variant, showing increased transmissibility and altered antigenicity compared to XBB.1.5.

bioRxiv · Aug 31, 2023 · PreprintMicrobiology

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

R. Uraki, S. Iida, P. J. Halfmann, S. Yamayoshi, Y. Hirata, K. Iwatsuki-Horimoto, M. Kiso, M. Ito, Y. Furusawa, H. Ueki, Y. Sakai-Tagawa, M. Kuroda, T. Maemura, T. Kim, S. Mine, , Y. Kawaoka

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

bioRxiv · Aug 26, 2022 · PreprintMicrobiology

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.

Y. Takamatsu, K. Omata, Y. Shimizu, N. Kinoshita-Iwamoto, M. Terada, T. Suzuki, S. Morioka, Y. Uemura, N. Ohmagari, K. Maeda, H. Mitsuya

This study compares the neutralizing activity of IgA and IgG antibodies against SARS-CoV-2 in COVID-19 patients and vaccine recipients, finding that IgA response is modest, peaks earlier, and declines faster than IgG.

bioRxiv · Jun 9, 2022 · PreprintMicrobiology

Comparison of de-duplication methods used by WHO Global Antimicrobial Resistance Surveillance System (GLASS) and Japan Nosocomial Infections Surveillance (JANIS) in the surveillance of antimicrobial resistance

T. Kajihara, K. Yahara, J. Stelling, S. R. Eremin, B. Tornimbene, V. Thamlikitkul, A. Hirabayashi, E. Anzai, T. Wakai, N. Matsunaga, K. Hayakawa, N. Ohmagari, M. Sugai, K. Shibayama

This study compares de-duplication methods from WHO GLASS and JANIS systems for AMR surveillance, finding small differences in patient counts and resistance percentages for E. coli.

PLOS ONE · Jun 26, 2020Peer-reviewedMicrobiology

The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

M. Yamamoto, M. Kiso, Y. Sakai-Tagawa, K. Iwatsuki-Horimoto, M. Imai, M. Takeda, N. Kinoshita, N. Ohmagari, J. Gohda, K. Semba, Z. Matsuda, Y. Kawaguchi, Y. Kawaoka, J.-i. Inoue

This study shows nafamostat inhibits SARS-CoV-2 infection in vitro by blocking TMPRSS2-mediated fusion, with potency exceeding its blood concentration, suggesting it as a potential COVID-19 treatment.

bioRxiv · Apr 22, 2020 · PreprintMicrobiology